Key result
A DNA-based genetic screening strategy achieved a genetic diagnosis in 36% of individuals with suspected myotonia congenita, identifying exon 8 of CLCN1 as a hot-spot for dominant mutations.
Cohort
Exon 8 of the CLCN1 gene is a hot-spot for dominant mutations in myotonia congenita, highlighting the importance of molecular genetic analysis for accurate genetic counseling.
Answers are grounded in this paper and cite their sources.
May support targeted CLCN1 testing for myotonia congenita diagnosis; leaves open validation in larger prospective cohorts.
Myotonia congenita (MC) is the commonest genetic skeletal muscle ion channelopathy. It is caused by mutations in CLCN1 on chromosome 7q35, which alter the function of the major skeletal muscle voltage-gated chloride channel. Dominant and recessive forms of the disease exist. We have undertaken a clinical, genetic and molecular expression study based upon a large cohort of over 300 UK patients. In an initial cohort of 22 families, we sequenced the DNA of the entire coding region of CLCN1 and identified 11 novel and 11 known mutations allowing us to undertake a detailed genotype-phenotype correlation study. Generalized muscle hypertrophy, transient weakness and depressed tendon reflexes occurred more frequently in recessive than dominant MC. Mild cold exacerbation and significant muscle pain were equally common features in dominant and recessive cases. Dominant MC occurred in eight families. We noted that four newly identified dominant mutations clustered in exon 8, which codes for a highly conserved region of predicted interaction between the CLC-1 monomers. Expressed in Xenopus oocytes these mutations showed clear evidence of a dominant-negative effect. Based upon the analysis of mutations in this initial cohort as well as a review of published CLCN1 mutations, we devised an exon hierarchy analysis strategy for genetic screening. We applied this strategy to a second cohort of 303 UK cases with a suspected diagnosis of MC. In 23 individuals, we found two mutations and in 86 individuals we identified a single mutation. Interestingly, 40 of the cases with a single mutation had dominant exon 8 mutations. In total 48 individuals (from 34 families) in cohort 1 and 2 were found to harbour dominant mutations (37% of mutation positive individuals, 30% of mutation positive families). In total, we have identified 23 new disease causing mutations in MC, confirming the high degree of genetic heterogeneity associated with this disease. The DNA-based strategy we have devised achieved a genetic diagnosis in 36% of individuals referred to our centre. Based on these results, we propose that exon 8 of CLCN1 is a hot-spot for dominant mutations. Our molecular expression studies of the new exon 8 mutations indicate that this region of the chloride channel has an important role in dominant negative interactions between the two chloride channel monomers. Accurate genetic counselling in MC should be based not only upon clinical features and the inheritance pattern but also on molecular genetic analysis and ideally functional expression data.
No takes yet. Share an insight, caveat, or question.
Fialho et al. (2007) conducted a cohort in Myotonia congenita. DNA-based genetic screening strategy for CLCN1 mutations was evaluated on Genetic diagnosis rate. A DNA-based genetic screening strategy achieved a genetic diagnosis in 36% of individuals with suspected myotonia congenita, identifying exon 8 of CLCN1 as a hot-spot for dominant mutations.
Synapse has enriched 10 related papers. Consider them for comparative context: